Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hepatitis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01757 Journal of Clinical Oncology - published online before print July 27, 2020 PMID (...) : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update , MD, MPH 1 x Jessica P. Hwang ; , MD, MPH 2 x Jordan J. Feld ; , MD 3 x Sarah P. Hammond ; , MD, MPH 4 x Su H. Wang ; , MD, MMM 5 x Devena E. Alston-Johnson ; , JD 6 x Donna R. Cryer ; , MD 7 x Dawn L. Hershman ; , MD, MPH 8 x Andrew P. Loehrer ; , MD 9 x Anita L. Sabichi ; , MD, MACP 10 x Banu E. Symington ; , MD, MPH 11 x Norah Terrault ; , MD, MAS 12 x Melisa L. Wong ; , PhD
Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement - The Journal of Heart and Lung Transplantation Go search , P418-432, May 01, 2020 Powered By Mendeley Share on Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Saima (...) Jeffrey Teuteberg,MD Maria Crespo,MD Haifa Lyster,PharmD Laura Lourenco,PharmD Sara Machado,MD Michael Shullo,Pharm D Matthew Hartwig,MD Miranda Peraskeva,MD Cameron Wolfe,MD Kiran Khush,MD Michael Ison,MD Shelley Hall,MD Joshua Mooney,MD Steve Ivulich,PharmD Marcelo Cypel,MD Victor Pretorius,MBBS Patricia Uber,PharmD Evan Kransdorf,MD, PhD Adam Cochrane,PharmD, MPH Alan Glanville,MD Jennifer Gray,PharmD Published: March 18, 2020 DOI: The advent of therapies for successful treatment of hepatitis C
Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) evidence to determine how often to screen persons at increased risk. What are other relevant USPSTF recommendations? The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus infection in adults, and HIV infection. These recommendations are available at . Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation
Screening for Hepatitis C Virus Infection Screening for Hepatitis C Virus Infection | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Screening for Hepatitis C Virus Infection Practice Advisory April 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The on March 2, 2020. New guidance from both the CDC and the USPSTF represent a change in routine screening (...) for HCV; both organizations now recommend HCV screening for all adults, including pregnant and nonpregnant individuals. The American College of Obstetricians and Gynecologists (ACOG) is actively reviewing the new guidance from the CDC and USPSTF. Updated guidance from ACOG will be posted on ACOG’s website and published in Obstetrics & Gynecology when available. ACOG is also reviewing its current guidance on the screening and management of hepatitis for pregnant individuals in ACOG Practice Bulletin
AASLD Guidelines for Treatment of Chronic Hepatitis B Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Norah A. Terrault, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Kyong-Mi Chang, 4 Jessica P. Hwang, 5 Maureen M. Jonas, 6 Robert S. Brown Jr., 7 Natalie H. Bzowej, 8 and John B. Wong 9 Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic (...) Hepatitis B (1) and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coin- fections, acute
Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing
Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility Major liver resection is associated with blood loss and transfusion. Observational data suggest that hypovolaemic phlebotomy can reduce these risks. This feasibility RCT compared hypovolaemic phlebotomy with the standard of care, to inform a future multicentre trial.Patients undergoing major liver resections were enrolled between June
Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment.Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation.45 general practices in South West England (22 randomised
Disorders of the Hepatic and Mesenteric Circulation ACG Clinical Guideline: Disorders of the Hepatic and Mesente... : American Journal of Gastroenterology ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800 (...) Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without
Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation
Givosiran (Givlaari) - acute hepatic porphyria Drug Approval Package: GIVLAARI (givosiran)Injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GIVLAARI (givosiran)Injection Company: Alnylam Pharmaceuticals Inc. Application Number: 212194 Approval Date: 11/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files
Hepatitis B Hepatitis B | Topics A to Z | CKS | NICE Search CKS… Menu Hepatitis B Hepatitis B Last revised in November 2019 Hepatitis B is an infectious disease of the liver caused by the hepatitis B virus. Diagnosis Management Prescribing information Background information Hepatitis B: Summary Hepatitis B is an infectious disease of the liver caused by the hepatitis B virus. The prevalence of people with antibodies to hepatitis B core antigen (anti-HBc) — a marker of current or previous (...) infection (seroprevalence) — is 1–2% in the UK. In parts of China and South Korea, the seroprevalence is 96%. In the UK, most new infections are acquired in adulthood. The source of infection is most commonly via sexual contact or sharing equipment for injecting drugs with other people with chronic hepatitis B. Acute hepatitis B symptoms and jaundice generally last for 1–3 months. Hepatitis B surface antigen (HBsAg) is cleared in around 95% of immunocompetent adults. Fulminant hepatitis occurs in less
Hepatitis A: What issues should I consider before prescribing analgesia? Analgesia | Prescribing information | Hepatitis A | CKS | NICE Search CKS… Menu Analgesia Hepatitis A: What issues should I consider before prescribing analgesia? Last revised in October 2019 What issues should I consider before prescribing analgesia? For prescribing information on paracetamol, ibuprofen, and codeine, see the CKS topic on . For more detailed prescribing information on nonsteroidal anti-inflammatory drugs
Hepatitis A: What issues should I consider before giving hepatitis A vaccine? Hepatitis A vaccine | Prescribing information | Hepatitis A | CKS | NICE Search CKS… Menu Hepatitis A vaccine Hepatitis A: What issues should I consider before giving hepatitis A vaccine? Last revised in October 2019 What issues should I consider before giving hepatitis A vaccine? What types of hepatitis A vaccine are available? There are several hepatitis A vaccines that are licensed for use in the UK. All (...) are inactivated, and prepared from different strains of the hepatitis A virus: Avaxim ® Havrix Monodose ® Havrix Junior Monodose ® Vaqta ® Vaqta Paediatric ® There are also combined hepatitis A and B vaccines: Twinrix ® (adult and paediatric formulations) Ambirix ® (paediatric formulation) A combined hepatitis A and typhoid vaccine (ViATIM ® ) is also available. [ ; ] What is the immunization schedule for the hepatitis A vaccine? The hepatitis A monovalent vaccine is given as two doses, 6–12 months apart